Navigation Links
Surveyed Oncologists Indicate that Avastin has Advantages over Temodar/Temodal in Increasing Overall Survival of High-Grade Glioma
Date:3/9/2009

A Drug That Improves Survival, When Added to Temodar/Temodal, Would Earn a 65 Percent Patient Share in the U.S. and a 30 Percent Patient Share in Europe in Newly Diagnosed Glioblastoma Multiforme, According to a New Report from Decision Resources

WALTHAM, Mass., March 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed oncologists identify a therapy's effect on overall survival as the attribute that most influences their prescribing decisions in high-grade glioma. Clinical data and the opinions of interviewed thought leaders indicate that Roche/Genentech/Chugai's Avastin has advantages in this attribute over Schering-Plough's Temodar/Temodal (temozolomide), the sales-leading agent in the market.

The new report entitled High-Grade Glioma: Prolonged Survival over Temozolomide Will Be Integral to Market Success finds that a therapy, when added to temozolomide, that increases median overall survival compared with temozolomide alone would earn a 65 percent patient share in the United States and a 30 percent share in Europe in newly diagnosed glioblastoma multiforme, according to surveyed U.S. and European oncologists.

In 2008, Decision Resources' proprietary clinical gold standard for high-grade glioma was Avastin. Although Avastin is not formally approved for the treatment of high-grade glioma, the drug is widely prescribed off-label as a result of promising Phase II clinical trial data. Based on expert opinion, Avastin will retain clinical gold standard status through 2017, owing to its high efficacy.

"Avastin emerges as our gold standard because of its efficacy, the attribute surveyed oncologists rated as the most important in treating high-grade glioma," said Decision Resources Analyst Ramya Kollipara, Ph.D. "Because the prognosis for high-grade glioma patients is so poor, interviewed thought leaders welcome Avastin's entry into this market because of its high efficacy, despite its associated side effects and less convenient delivery."

About the Report

High-Grade Glioma: Prolonged Survival over Temozolomide Will Be Integral to Market Success is a DecisionBase 2009 report. DecisionBase 2009 is a decision-support tool that provides in-depth analysis of unmet need, physician expectations of new therapies and commercial dynamics to help pharmaceutical companies optimize their investments in drug development.

The report can be purchased by contacting Decision Resources. Members of the media may request an interview with an analyst.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                            Decision Resources, Inc.
    Christopher Comfort                           Elizabeth Marshall
    781-296-2597                                  781-296-2563
    ccomfort@dresources.com                       emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. World Vision Index of Concern: Half of Americans Surveyed Said They Would Be Willing to Pay More Taxes to Combat AIDS
2. Eighty-Nine Percent of Surveyed Rheumatologists Say They Will Prescribe Roche/Chugais Actemra for Rheumatoid Arthritis
3. Surveyed Neurologists in Both the U.S. and Europe Would Welcome an Antiepileptic Drug That is Administered Once-Daily
4. Half of Full-Time Employees Surveyed Dont Understand Health Insurance Coverage for Cancer-Related Medical Expenses
5. Surveyed Gastroenterologists Indicate That Humira Has Advantages Over Remicade in Maintaining Clinical Remission of Crohns Disease
6. Less Than Two-Thirds of Surveyed Pharmacy Directors Expect to Reimburse Both Onglyza and Alogliptin Once They are Available for the Treatment of Type 2 Diabetes
7. As a Result of the Jupiter Trial, 65 Percent of Surveyed MCO Pharmacy Directors Will Reimburse Crestor for Patients with Elevated hsCRP
8. Oncologists are critical in managing psychiatric disorders in patients with advanced cancer
9. Jefferson radiation oncologists use real-time system to plant seeds against cancer
10. Society of Gynecologic Oncologists Provides Guidelines for Offering Genetic Risk Assessment to Women With a Personal or Family History of Breast, Ovarian, Uterine or Colorectal Cancer
11. Leading Oncologists from Across the Country Hold Emergency Meeting on New Government Reimbursement Policy for Medicare Patients with Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/24/2016)... CA (PRWEB) , ... June 24, 2016 , ... A ... procedures that most people are unfamiliar with. The article goes on to state that ... but also many of these less common operations such as calf and cheek reduction. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg ... Legal Elite. The attorneys chosen by their peers for this recognition are considered among ... Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite Hall ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ., ... developing innovative inhaled drugs, announced today that it was ... Investments reconstituted its comprehensive set of U.S. and ... "This is an important milestone for Pulmatrix," said Chief ... shareholder awareness of our progress in developing drugs for ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: